Search Result

Results for "

MM.1S

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (9) Arenavirus (1) Autophagy (1) Bcl-2 Family (1) Casein Kinase (2) Caspase (1) CDK (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (2) Epigenetic Reader Domain (4) FLT3 (1) HDAC (3) Histone Demethylase (7) IAP (1) IKK (1) IKZF Family (1) JAK (1) JNK (1) Ligands for E3 Ligase (2) Molecular Glues (4) Monoamine Oxidase (1) mTOR (1) Phosphodiesterase (PDE) (2) PROTACs (5) Proteasome (2) SOD (1)
By Research Areas:	Cancer (34) Infection (1) Inflammation/Immunology (1) Neurological Disease (1)

By Targets:

Akt (1)

Apoptosis (9)

Arenavirus (1)

Autophagy (1)

Bcl-2 Family (1)

Casein Kinase (2)

Caspase (1)

CDK (1)

DNA Alkylator/Crosslinker (2)

DNA/RNA Synthesis (2)

Epigenetic Reader Domain (4)

FLT3 (1)

HDAC (3)

Histone Demethylase (7)

IAP (1)

IKK (1)

IKZF Family (1)

JAK (1)

JNK (1)

Ligands for E3 Ligase (2)

Molecular Glues (4)

Monoamine Oxidase (1)

mTOR (1)

Phosphodiesterase (PDE) (2)

PROTACs (5)

Proteasome (2)

SOD (1)

By Research Areas:

Cancer (34)

Infection (1)

Inflammation/Immunology (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149924

CST626	PROTACs IAP	Cancer
CST626 (Compound 9) is a pan-IAP degrader PROTAC. CST626 degrades XIAP, cIAP1 and cIAP2 with DC₅₀s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively ^[1].

HY-145322

TMX-4116	Casein Kinase Molecular Glues	Cancer
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC₅₀s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma ^[1].

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active *LSD1/HDAC6/MAO-A* inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma ^[1] .

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma ^[1].

HY-161101

MG degrader 1	PROTACs IKZF Family	Cancer
MG degrader 1 (Compd E14) is a PROTAC degrader of IKZF3, *GSPT1, and GSPT2* with an EC₅₀ value of 1.385 nM in MM.1S cells ^[1].

HY-132857A

ZXH-4-130 TFA 1 Publications Verification	PROTACs	Neurological Disease
ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC). ZXH-4-130 TFA induces ~80% CRBN degradation at 10 nM in MM1.S cells ^[1].

HY-145667

Biotinylated-JQ1 1 Publications Verification Biotin-JQ1	Epigenetic Reader Domain	Cancer
Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC₅₀ of 0.4 μM ^[1].

HY-157216

HDAC1 Degrader-1	HDAC	Cancer
HDAC1 Degrader-1 (compound 1a) is an *HDAC1* degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells ^[1].

HY-155671

HDAC6-IN-18	HDAC	Cancer
HDAC6-IN-18 (Compound 4) is a first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity. HDAC6-IN-18 has HDAC6 inhibitory activity in RPMI8266, U266 and MM.1S cells with IC₅₀ values of 0.17, 0.7 and 0.42 μM, respectively ^[1].

HY-144763

XPO1-IN-1	Apoptosis	Cancer
XPO1-IN-1 (compound D4) is an orally active and potent *XPO1* inhibitor, with an IC₅₀ of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research ^[1].

HY-115445

LCS-1 1 Publications Verification	Apoptosis SOD	Cancer
LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells ^[1] .

HY-147158

ZXH-1-161	Molecular Glues Ligands for E3 Ligase	Cancer
ZXH-1-161 is a potent cereblon (CRBN) modulator with an IC₅₀ value of 39 nM in MM1.S wild type cells. ZXH-1-161 has selective degradation activity towards GSPT1. ZXH-1-161 can be used for researching multiple myeloma ^[1].

HY-144369

Proteasome-IN-4	Proteasome	Cancer
Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC₅₀=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research ^[1].

HY-125051

SG3-179	JAK FLT3	Cancer
SG3-179 is a potent inhibitor against the BET bromodomain proteins. SG3-179 is also a JAK2 and FLT3 inhibitor. SG3-179 causes a rapid reduction in HOXB13 protein expression. SG3-179 is promising for research of multiple myeloma (MM1.S) ^[1] .

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-102047B

KDOAM-25 citrate 4 Publications Verification	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-160502

CST967	PROTACs	Cancer
CST967 (Compound 17) is a USP7 PROTAC degrader, and increasing the PROTAC concentration can enhance the degradation rate of USP7. CST967 can be used in cancer research ^[1].

HY-161250

Pomalidomide-NH-PEG6-amide-C2-CPI-1612	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC₅₀ of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells ^[1].

HY-149930

YL5084	JNK Apoptosis	Cancer
YL5084, a covalent JNK inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC₅₀s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner ^[1].

HY-153226

BET-IN-14	Epigenetic Reader Domain	Cancer
BET-IN-14 is an orally active pan BET inhibitor (IC₅₀: 5.35 nM). BET-IN-14 has anti-cancer activity ^[1].

HY-111790

M3258 1 Publications Verification	Proteasome Apoptosis	Cancer
M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC₅₀=3.6 nM) and cellular (IC₅₀=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells ^[1] .

HY-125927

8-Aminoadenosine 1 Publications Verification 8-NH2-Ado	DNA/RNA Synthesis Akt mTOR Autophagy Apoptosis	Cancer
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks Akt/mTOR signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity ^[1] .

HY-138691

JQKD82 JADA82; PCK82	Histone Demethylase	Cancer
JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma ^[1].

HY-142704

BRD4 D1-IN-1	Epigenetic Reader Domain	Cancer
BRD4 D1-IN-1 is a selective BRD4 D1 inhibitor (IC₅₀<0.092 µM). BRD4 D1-IN-1 has 18 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC ^[1].

HY-142705

BRD4 D1-IN-2	Epigenetic Reader Domain	Cancer
BRD4 D1-IN-2 (compound 26) is a potent and selective BRD4 D1 inhibitor (IC₅₀<0.092 µM). BRD4 D1-IN-2 has 15 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC ^[1].

HY-143715

Cereblon inhibitor 1	Ligands for E3 Ligase	Cancer
Cereblon inhibitor 1, an isoindoline derivative, is a cereblon E3 ubiquitin ligase modulating agent. Cereblon inhibitor 1 has the potential for cancer research.

HY-138691A

JQKD82 trihydrochloride JADA82 trihydrochloride; PCK82 trihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma ^[1].

HY-138691B

JQKD82 dihydrochloride JADA82 dihydrochloride; PCK82 dihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) dihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 dihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma ^[1].

HY-145320

TMX-4113	Molecular Glues Phosphodiesterase (PDE) Casein Kinase	Cancer
TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer ^[1].

HY-105019A

Melflufen hydrochloride 1 Publications Verification Melphalan flufenamide hydrochloride	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells ^[1] .

HY-105019

Melflufen Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells ^[1] .

HY-15473A

MLN120B dihydrochloride Maximum Cited Publications 25 Publications Verification ML120B dihydrochloride	IKK	Inflammation/Immunology Cancer
MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC₅₀ of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis ^[1] .

HY-163856

CDK7-IN-30	Apoptosis CDK	Cancer
CDK7-IN-30 (Compound 22) is a CDK7 inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis and has anti-cancer activity and can be used in cancer research ^[1].

HY-13560

AVN-944 4 Publications Verification VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Infection Cancer
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research ^[1] .

Cat. No.	Product Name	Target	Research Area

HY-105019

Melflufen Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells ^[1] .

8-Aminoadenosine 1 Publications Verification 8-NH2-Ado	Structural Classification Natural Products Source classification Endogenous metabolite	DNA/RNA Synthesis Akt mTOR Autophagy Apoptosis
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks Akt/mTOR signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks